A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

Nektar’s shares have surged more than twofold after a Phase IIb study of its atopic dermatitis (AD) therapy rezpegaldesleukin ...

Despite Nektar’s share price shooting up as much as 175% on Tuesday, William Blair maintained that “there is an absence of ...

Nektar reported positive Phase 2b trial data for rezpegaldesleukin in atopic dermatitis, showing strong efficacy and a ...

Nektar Therapeutics stock launched Tuesday after the biotech company hit every goal in a midstage study of its eczema ...

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

Nektar Therapeutics shares doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a ...

Nektar Therapeutics (NKTR) saw its stock surge 86% Tuesday morning after reporting strong midstage trial results for its ...

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced statistically significant data from the 16-week ...

Nektar Therapeutics is enjoying the sweet taste of clinical trial success after years of swallowing bitter pills. | Nektar Therapeutics is enjoying the sweet taste of clinical trial success after ...

The IGA and EASI are tools used for measuring and monitoring eczema by looking at thickening and hardening, redness, and scaling of your skin lesions. EASI also takes into account where the ...